UBS AM’s OptimizeRx OPRX Stock Holding History

UBS AM’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.9K	Buy	940 +301	+47%	+$2.79K	﹤0.01%	3428
2025 Q4	$7.83K	Buy	+639	New	+$10.4K	﹤0.01%	2900
2024 Q4	–	Sell	-310,000	Closed	-$2.39M	–	2734
2024 Q3	$2.39M	Hold	310,000	–	–	﹤0.01%	1951
2024 Q2	$3.1M	Buy	+310,000	New	+$3.41M	﹤0.01%	1758
2022 Q3	–	Sell	-8,262	Closed	-$226K	–	2765
2022 Q2	$226K	Hold	8,262	–	–	﹤0.01%	2557
2022 Q1	$312K	Sell	8,262 -5,078	-38%	-$225K	﹤0.01%	2586
2021 Q4	$829K	Buy	13,340 +3,305	+33%	+$250K	﹤0.01%	2306
2021 Q3	$858K	Buy	10,035 +233	+2%	+$14.6K	﹤0.01%	2251
2021 Q2	$607K	Buy	+9,802	New	+$499K	﹤0.01%	2452

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM's OPRX Position: Q1 2026 in Review

UBS AM increased its OptimizeRx (OPRX) stake by 47% in Q1 2026, buying an estimated $2.79K and bringing the position to 940 shares worth $5.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

UBS AM first reported a position in OPRX in Q2 2021 and has held it in 9 quarters since. The position peaked at $3.1M in Q2 2024. 128 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

UBS AM held 940 shares of OptimizeRx worth $5.9K as of Q1 2026.
UBS AM bought 301 OptimizeRx shares in Q1 2026, an estimated $2.79K.
OptimizeRx made up ﹤0.01% of UBS AM's portfolio in Q1 2026, its #3428 holding.
UBS AM first reported a position in OptimizeRx in Q2 2021 and has held it in 9 quarters since.
UBS AM's OptimizeRx position peaked at $3.1M in Q2 2024.
128 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.